Journal
FRONTIERS IN NEUROSCIENCE
Volume 12, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fnins.2018.00681
Keywords
beta-amyloid; synthetic peptides; receptor for advanced glycation end products; Alzheimer's disease; primary cell culture
Categories
Funding
- Russian Science Foundation [14-50-00131]
- RFBR/National Intellectual Development grant [17-34-80016]
- RFBR [16-04-00944]
- Russian Science Foundation [14-50-00131] Funding Source: Russian Science Foundation
Ask authors/readers for more resources
Receptor for advanced glycation end products (RAGE) is involved in the pathogenesis of Alzheimer's disease. We have previously revealed that RAGE fragment sequence (60-76) and its shortened analogs sequence (60-70) and (60-65) under intranasal insertion were able to restore memory and improve morphological and biochemical state of neurons in the brain of bulbectomized mice developing major AD features. In the current study, we have investigated the ability of RAGE peptide (60-76) and five shortened analogs to bind beta-amyloid (A beta) 1-40 in an fluorescent titration test and show that all the RAGE fragments apart from one [sequence (65-76)] were able to bind A beta in vitro. Moreover, we show that all RAGE fragments apart from the shortest one (6062), were able to protect neuronal primary cultures from amyloid toxicity, by preventing the caspase 3 activation induced by A beta 1-42. We have compared the data obtained in the present research with the previously published data in the animal model of AD, and offer a probable mechanism of neuroprotection of the RAGE peptide.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available